Boston Scientific has a new cardiac rhythm and vascular (CRV) business unit, which is the combination of its cardiovascular and cardiac rhythm management divisions. The Natick, Mass.-based company highlighted the change at the recent American College of Cardiology (ACC) conference in Atlanta.
“The move combines two organizations that are 1600-plus sales representatives strong, which will enable us to better serve our customers," Jeff LeMaster, vice president for Boston Scientific’s cardiology division, told Cardiovascular Business News.
“It also affords us the opportunity to invest robustly in our new product pipeline,” he said. “Between the two divisions, we’re investing about $650 million a year in R &D.”
LeMaster said the move will allow the company to continue to invest at a high level by realizing savings with some of its shared services that may overlap. “Eighty percent of the company now is one division,” he said.